TY - T1的过度使用短效β2 <子> < /订阅>受体激动剂在哮喘恶化的风险和死亡率增加有关:一个全国性的队列研究的全球萨拜娜项目JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01872 -2019欧元六世- 55 - 4 SP - 1901872 AU -明亮。Nwaru AU -马格努斯埃克斯特龙盟Pal Hasvold AU -功能弗雷德里克·但盟Gunilla Telg盟Christer詹森- Y1 - 2020/04/01 UR - //www.qdcxjkg.com/content/55/4/1901872.abstract N2 -背景过度使用短效β2-agonists(沙巴)可能表明贫穷哮喘控制和不良健康结果。当代以人群为基础的数据使用,危险因素和萨巴的影响(在)用于哮喘急性加重和死亡率稀缺,促使全球萨比娜的起始(萨巴使用哮喘)计划。方法通过将数据从瑞典国家注册、哮喘患者12-45岁两个或两个以上的阻塞性肺疾病药物的集合包括2006 - 2014年期间。萨巴过度被定义为集合两萨巴多罐包含后基线期一年。萨巴使用分成3 - 5、6 - 10和≥11罐/基准年。Cox回归是用来检查萨巴之间的联系使用和恶化(住院治疗上和/或口服皮质类固醇索赔)和死亡率。结果分析包括365 324名哮喘患者(平均年龄27.6岁;55%女性);平均随访85.4个月。过度使用萨巴30%,21%每年收集3 - 5罐,7%每年收集6 - 10罐和2%每年收集≥11罐。越来越多的萨巴收集罐与恶化的风险增加相关,如下。3 - 5罐:风险比(人力资源)1.26 (95% CI 1.24 - -1.28); 6–10 canisters: 1.44 (1.41–1.46); and ≥11 canisters: 1.77 (1.72–1.83), compared to two or fewer canisters per year. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed), as follows. 3–5 canisters: HR 1.26 (95% CI 1.14–1.39); 6–10 canisters 1.67 (1.49–1.87); and ≥11 canisters: 2.35 (2.02–2.72) compared to two or fewer canisters per year.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.One-third of asthma patients in Sweden were SABA overusers (three or more canisters per year), of whom 28% had no collection of anti-inflammatory drugs. Higher SABA use was associated with increased exacerbation and mortality risks. http://bit.ly/2PqqSKn ER -